BioPorto A/S Overview
Pro stress-test →BioPorto A/S is an in-vitro diagnostics company that focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. The Company's flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and management of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences if not identified and treated early.
Strategic Profile
Pro stress-test →The company looks to convert rising awareness to sustainable recurring revenues in the AKI diagnostic market, estimated to have a total addressable market (TAM) of USD 3.0 billion and a 5% CAGR, supported by a shift in diagnostic paradigms. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need.
Competitive Landscape
Pro stress-test →The company derives a majority of its revenue from North America, competing in the acute kidney injury diagnostics space against legacy clinical chemistry players and emerging biomarker competitors. The Roche partnership provides distribution but also creates dependency risk. The ~$3B TAM supports multiple players but first-mover advantage in AKI biomarkers remains a competitive moat.
Industry Context
BioPorto A/S operates in In Vitro Diagnostics (IVD) / Clinical Laboratory Testing.
Key facts
Founded: 1917 · Headquarters: Hellerup, Denmark · Employees: 48 · Revenue: $5.4M · Market cap: $79.3M